Texas Oncology's Virtual Navigation Pilot for Oral Oncolytics: What the Report Shows

Targeted Oncology published a commentary on October 13, 2026, by Cassidy Davis, BSN, RN, OCN, ONN-CG, describing a virtual care navigation pilot at Texas Oncology, a practice in The US Oncology Network ^[1]. Between May 2025 and January 2026, the pilot supported 740 patients taking oral oncolytics across 11 community sites, and the article draws its figures from Texas Oncology's proprietary company data ^[1]. Oral oncolytics are cancer medicines taken by mouth and largely self-administered at home, so patients often have fewer in-person touchpoints with their care team than those receiving infusions ^[1].

How the pilot was organised

The commentary describes a model built on a small centralised team, automated scheduling and structured screening, and offers it as a possible model for organisations supporting patients on self-administered oral therapies ^[1]:

• A small centralised unit of two registered nurse navigators and one non-clinical lay navigator served a network of roughly 40 physicians ^[1].
• Each patient was followed for a 90-day episode of care, with about 20 automated touchpoints timed to key points in treatment, replacing tracking by spreadsheet ^[1].
• Staff stepped in at defined moments to provide education, speed insurance prior authorisations, secure the first refill and monitor ongoing adherence ^[1].
• Navigators used Medicare's 26-question Health-Related Social Needs assessment to identify problems such as food, housing or transport instability ^[1].
• Patients were enrolled on electronic patient-reported outcomes (ePROs), meaning digital symptom reports that patients submit between visits so the team can respond ^[1].

What the article reports

The one quantified outcome is a 491% increase in active patient enrollment on the ePRO platform ^[1]. The article states that earlier detection of symptoms may have helped reduce emergency department and urgent care use, but it gives no visit counts or rates ^[1]. It also says total medical spending for enrolled patients often stayed below that of non-enrolled patients despite added navigation fees, again without figures ^[1]. The author attributes the program's financial viability to aligning its services with the Centers for Medicare & Medicaid Services 2024 Principal Illness Navigation billing codes ^[1]. The program was named second runner-up for the 2026 American Nurse Journal All-Pro Nursing Team Award ^[1].

Why it matters to care teams

The article frames the problem with adherence figures from an Advisory Board report: nonadherence to oral oncolytics averaging 48.1%, and 18% of patients stopping treatment within 90 days ^[1]. Those figures describe the background need, not results of this pilot ^[1]. The practical point for clinic leads is the operating model: the author credits separating virtual navigators from on-site clinical duties with enabling proactive outreach rather than reactive, clinic-dependent contact ^[1]. For organisations caring for patients on self-administered oral therapies, the author presents this combination of scheduled check-ins over a defined episode and structured social-needs screening as a model worth considering ^[1].

What to watch next

The article labels May 2025 to January 2026 the program's Early Phase, so later reporting may follow ^[1]. The author describes the model as "a scalable blueprint for expanding quality care beyond traditional clinical settings," a claim that would be easier to judge with published adherence, acute-care and cost data ^[1]. Another point to watch is whether reliance on the 2024 navigation billing codes holds up elsewhere, since the article reports viability for this one practice only ^[1].

Limitations

This is a practice commentary based on proprietary data, not a peer-reviewed study, and it reports no study design, comparison method, confidence intervals or p-values ^[1]. The source does not explain how enrolled and non-enrolled patients were compared or whether they differed at the outset, so lower spending or acute-care use cannot be attributed to the program ^[1]. The only numeric outcome concerns platform enrollment, a process measure rather than a clinical one, and the article reports no adherence rate for enrolled patients ^[1].